12/03 18:41 Inhale <INHL.O> poised for profits - BusinessWeek
NEW YORK, Dec 3 (Reuters) - Inhale Therapeutic Systems Inc.
<INHL.O> could be poised to reap big profits and a run-up in its stock
price after it brings a product to market that enables patients to inhale
drugs such as insulin, the December 14 issue of BusinessWeek
argues.
What's more, Pfizer Inc. <PFE.N> is betting a lot of money that Inhale
will succeed, the magazine's closely watched Inside Wall Street
column said.
Pfizer signed a pact with Germany's Hoechst Marion Rousel to build a
jointly owned plant in Frankfurt, costing anywhere from $500 million to
$800 million to build, to produce bulk insulin, the article said.
And two companies also plan to help Inhale develop and promote
inhaled insulin, the article added. "It is unusual for a big
pharmaceutical house to plunk down hundreds of millions for a
product still in clinical trials," the article said.
An unnamed New York money manager said conservatively Inhale
could stand to earn $45 million a year from the new product on a
pre-tax basis, the article said.
If so, Inhale's stock would be worth 45 to 50 rather than under 33
where it is trading now, according to the money manager, the article
said.
moneynet.com@NEWS-P2&Index=0&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=&NAVSVC=News\Company |
